AudioMedica News: Recent Episodes
AudioMedica.com
BRIGHTON, UK—In underserved communities throughout the world low rates of early breast cancer detection are key drivers of mortality, according to the findings of research from Uganda, the United Kingdom and Nigeria. A range of low cost community-based interventions could …
Audio Journal of Oncology, February 14 2023, Reporting from the American Society of Hematology Annual Meeting (ASH), December 2022
An interview with Amy A. Kirkwood MSc, Senior Statistician at the Cancer Research UK & UCL Cancer Trials Centre, University College, …
ARROS-1 Study Finds ROS1 Tyrosine Kinase Inhibitor Has Promise as a Tumor Agnostic Therapy
BARCELONA, Spain—Findings from a study of a new investigational therapy targeting the ROS-1 receptor tyrosine kinase—mutated in some cancers—were reported at the 2022 EORTC-NCI-AACR Molecular …
Pan-AKT Inhibitor Tumor Agnostic Targeting was Safe and Effective in Phase One Study
BARCELONA, Spain—Patients with solid tumors expressing mutated AKT oncogenes responded to therapy with a pan-AKT inhibitor ipatasertib in a phase one study reported at the 2022 EORTC—NCI—AACR …
BARCELONA, Spain—Although having a mutated MYC molecule is a distinguishing molecular factor in many solid tumors it has been considered “undruggable” — having a shortage of potential and actual mechanisms for cancer inhibition. But it now looks as though MYC …
New Molecular Drug has Clinical Activity in Hepatocellular Carcinoma
Interview with:
Maria Reig MD PhD, Professor and Head of the Barcelona Clinic Liver Cancer (BCLC) Unit, Hospital Clinic Barcelona at Barcelona University, Spain.
BARCELONA, Spain—A phase one study of new …
PARIS, France—Patients who had cell therapy as second-line treatment for their advanced melanoma lived twice as long without disease progression compared with those who merely continued with pure immunotherapy. This finding came from a phase three randomized study reported at …
BARCELONA, Spain—Next generation sequencing is now an essential part of care for glioma in adults, according to research on BRAF targeting as treatment for this disease reported at the 2022 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium.
Karisa Schreck MD …
PARIS, France—the open-label international phase three randomized IPSOS study reported at the 2022 European Society for Medical Oncology congress that patients with non-small cell lung cancer who were not fit enough to be recommended standard platinum doublet chemotherapy lived longer …
Audio Journal of Oncology: October, 2022:
Breast Conservation: Machine-Learning Helps De-Escalate Breast Cancer Therapy
André Pfob, Clinical Research Assistant in the University Breast Unit of Heidelberg University Hospital, Germany tells the Audio Jounal of Oncology’s correspondent Peter Goodwin about the …
Breast Conservation: Machine-Learning Helps De-Escalate Breast Cancer Therapy
André Pfob, Clinical Research Assistant in the University Breast Unit of Heidelberg University Hospital, Germany tells the Audio Jounal of Oncology’s correspondent Peter Goodwin about the machine learning techniques his group …
221014 André Pfob AJO PRODUCTION MASTER
PARP-Inhibition Beyond Initial Therapy Extends Life with Advanced Ovarian Cancer
PARIS, France—Long remissions and “potential cures” were reported at the 2022 Annual Meeting of the European Society for Medical Oncology (ESMO) in patients with newly diagnosed advanced ovarian cancers …
280909 Paul Di Silvestro ESMO FRIDAY AJO Podcast MASTER
Audio Journal of Oncology: Progression to Acute Myeloid Leukemia Explained by Multi Omics Analysis
A new research method has elucidated cellular processes (involving mutated TP53 oncogene) that can convert a relatively benign myeloproliferative neoplasm into a threatening acute myeloid leukemia.…
Audio Journal of Oncology
September 9, 2022
“PM 2.5” Evidence Links Particulate Air Pollution to Non-Small Cell Lung Cancer
By Peter M Goodwin
PARIS, France—Particulate air pollution was identified as a key step in malignant transformation from benign DNA to …
220909 Charles Swanton ESMO Podcast PRODUCTION MASTER
The AJO INTERVIEW—Charles Swanton FRCP BSc PhD, Professor and Senior Group Leader of the Francis Crick Institute in London and European Society for Medical Oncology (ESMO) 2022 Scientific Co-Chair, is interviewed during the Annual Congress of ESMO in Paris …
220909 Charles Swanton ESMO AJO Podcast PRODUCTION MASTER
UK & NETHERLANDS—Following the the AJO Podcast interview with Professor Harry de Koning MD PhD, from the Erasmus University in Rotterdam, who discussed his research published in the New England Journal of Medicine that supports the widespread introduction of computed …
Second Study Confirms Lung Cancer CT Screening Cuts Deaths
NETHERLANDS—Erasmus University Medical Center, Rotterdam—Research published in the New England Journal of Medicine has confirmed the viability of computed tomographic (CT) screening for detecting cases of lung cancer early in high-risk …
Harry J. de Koning MD PhD
Audio Journal of Oncology
SAN DIEGO—The first-line treatment of choice for older patients with chronic lymphocytic leukemia (CLL) should now be single agent ibrutinib according to conclusions drawn from the Alliance North American Intergroup Study A041202 reported at …
Woyach AJO Prouction MASTER
Microbiome Diversity Key To Survival After Allogeneic Hematopoietic Cell Transplantation
The Audio Journal of Oncology Podcast
SAN DIEGO—Overall survival after allogeneic hematopoietic cell transplantation (allo-HCT) was found to be adversely influenced by a lack of diversity in the intestinal microbiota—before, …
Jonathan Peled AudioMedica AJO Podcast
From: January 2020 Edition of Pediatric Physical Therapy journal:
CINCINNATI—Julie Badylak PT and Rebecca Durham Reder OTD, OTR/L from Cincinnati Children’s Hospital discuss the findings of their team’s report in the journal Pediatric Physical Therapy on the assessment of tasks …
Audio Journal of Oncology
Reporting from 2018 annual meeting of the American Society of Hematology
SAN DIEGO—Individualized therapy decisions that are founded on “genomic fingerprint” data can now be made within seven days for most patients with suspected diagnoses of …
John C Byrd Sunday ASH AJO WordPress MASTER
SAN DIEGO—Patients 70 years old and younger with previously untreated chronic lymphocytic leukemia (CLL) lived longer and had progression of their disease delayed when treated with ibrutinib (an irreversible inhibitor of Bruton’s tyrosine kinase [BTK]) combined with the anti-CD 20 …
SAN DIEGO—Patients 70 years old and younger with previously untreated chronic lymphocytic leukemia (CLL) lived longer and had progression of their disease delayed when treated with ibrutinib (an irreversible inhibitor of Bruton’s tyrosine kinase [BTK]) combined with the anti-CD 20 …
Shanafelt AJO PodcastMASTER
MUNICH—A “salutary lesson” was reported by researchers investigating therapy for oropharyngeal cancer at the 2018 annual congress of the European Society for Medical Oncology (ESMO). It came from results of the De-ESCALaTE HPVstudy that found patients with low-risk head and …
Hisham Mehanna discusses head and neck cancer de-escalation
MUNICH—A leading European oncologist acknowledged the impressive life-extending potential of new drug combinations for metastatic renal cell carcinoma discussed at the 2018 annual congress of the European Society for Medical Oncology (ESMO). Progress was reported with purely immunological approaches—using two …
John Haanen Audio Journal of Oncology
MUNICH— A doubling of progression free survival (PFS) and objective response rate (ORR) was observed in patients who had their previously untreated advanced renal cell cancer (RCC) treated with a combination of the vascular endothelial growth factor (VEGF) inhibitor axitinib …
Robert Motzer ESMO AJO
MUNICH— Anaplastic lymphoma kinase (ALK) inhibitors are as effective in “real world” clinical use for treating patients with non-small cell lung cancer (NSCLC) who test positive for ALK gene rearrangements as they are in clinical studies—even though randomized trials “cherry …
Mohammad Jahanzeb AJ0
MUNICH—The role of poly ADP ribose polymerase (PARP) inhibitors for treating newly diagnosed advanced ovarian cancer was under review at the 2018 annual congress of the European Society for Medical Oncology (ESMO) in the light of findings from the SOLO1 …
Jonathan Ledermann AJO
BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib
MUNICH—An “unprecedented improvement” in progression free survival (PFS) was observed in the randomized controlled double-blind phase three SOLO1 study of women with newly diagnosed ovarian cancer who had BRCA1/2 mutations and …
Kathleen Moore OLAPARIB FIRST LINE IN OVAIAN CANCER
MUNICH— Immunotherapy with the anti programmed death ligand 1 (PD-L1) checkpoint inhibitor atezolizumab in combination with nab-paclitaxel chemotherapy prolonged progression-free survival (PFS) among patients with metastatic triple-negative breast cancer in the randomized phase three IMpassion130 trial reported at the 2018 …
Peter Schmid AJO Atezolizumab Extends Lif e in Triple Negative Breast Cancer
MUNICH—A combination of the phosphoinositide 3-kinase (PI3K) inhibitor alpelisib plus fulvestrant significantly extended progression free survival (PFS) compared to placebo plus fulvestrant in patients with hormone receptor positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) advanced breast …
Fabrice André ESMO 2018 AJO Genomic Breast Cancer Targeting
MUNICH—Patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer who were treated with a combination of the cyclin dependent kinase (CDK) 4/6 inhibitor palbociclib in combination with fulvestrantlived longer than those receiving a placebo …
Massimo Cristofanilli AJO PRODUCTION MASTER
MUNICH—More than four years median overall survival was reported in patients treated with an inhibitor of anaplastic lymphoma kinase (ALK) for their ALK gene rearranged non-small cell lung cancer (NSCLC) in a single-arm phase two study reported at the 2018 …
181019 Enriqueta Felip AJO PRODUCTION MASTER
Reporter: Sarah Maxwell
BARCELONA—Pembrolizumab did not significantly improve overall survival (OS) or progression free survival (PFS) compared with paclitaxel as second-line therapy in patients with advanced gastric or gastro-esophageal junction cancer that had progressed after one line of chemotherapy (containing …
Kohei Shitara Audio Journal of Oncology
BARCELONA—Oral cabozantinib “significantly improved” overall survival (OS) and progression free survival (PFS) compared to placebo in patients with advanced hepatocellular carcinoma(HCC) whose disease had progressed despite sorafenib therapy in the phase 3 CELESTIAL trial reported to the 2018 ESMO World …
Pilippe Marle AJO PRODUCTION MASTER
BARCELONA—A chemotherapy combination consisting of trifluridine with tipiracil showed a “clinically meaningful and statistically significant” improvement in overall survival (OS) and progression free survival (PFS) compared with placebo in patients with heavily-pretreated metastatic gastric cancer (mGC) refractory to standard therapies …
Josep Tabernero Audio Journal of Oncology
CHICAGO—A 25 per cent risk reduction for esophageal cancer was found to be associated with prophylactic therapy consisting of a proton pump inhibitor (PPI) and aspirin in the phase three randomized ASPECT multicenter study from the United Kingdom reported at …
Jaanusz Jankowski AJO PRODUCTION MASTER 8'54
CHICAGO—Patients with resectable and “borderline resectable” pancreatic cancers treated with chemoradiation before surgery (followed by adjuvant chemotherapy) had significantly improved outcomes compared to those randomized to have surgery first and adjuvant chemotherapy in the Dutch Pancreatic Cancer Group’sPREOPANC-1 randomized, controlled, …
180722 Geertjan Van Tienhoven AJO Production Master
CHICAGO—Patients with newly-diagnosed hormone-sensitive metastatic prostate cancer (mPC) who had prostate radiotherapy (RT) before their androgen deprivation therapy (ADT) lived longer than those treated with standard ADT alone in a retrospective analysis—the largest single-center experience to date of primary tumor-directed …
Audio J Oncology Scott Morgan PRODUCTION MASTR
CHICAGO—Clinically targetable mutations were identified and patient subgroups pinpointed by whole genome sampling (WGS) of castration-resistant metastatic prostate cancer (mPC) in a study reportedatthe 2018 Annual Meeting of the American Society of Clinical Oncology. (https://meetinglibrary.asco.org/record/160671/abstract)
Lisanne F van …
Lisanne F van Dessel AJO Production MASTER
CHICAGO—A gene test that predicts for relapse in women with estrogen receptor positive early breast cancer can identify patients with low-risk disease who could safely avoid extending their endocrine therapy beyond the standard five years, according to study findings reported …
Graham Poage ASCO AJO Production MASTER
CHICAGO—Men who had breast-conserving therapy (BCT) including radiation for their early breast cancer lived longer than those who had total or partial mastectomy—with or without radiation—in findings from a large retrospective survey of male breast cancer reported at the 2018 …
Sarah Bateni & Candice Sauder AJO
CHICAGO—A “cluster randomized controlled trial” of treatment for patients with advanced cancers found that the use of standardized geriatric assessments significantly increased the number and quality of discussions about age-related concerns in comparison with usual care and also resulted in …
Supriya Gupta Mohile AJO INTERVIEW Production MASTER
CHICAGO—Women and men were treated differently for the same tumor stages of head and neck cancer (HNC) and had different outcomes in a study with patients surveyed over a fifteen-year period in Santa Clara, California. The findings—using the generalized competing …
Jed Katzel AJO PRODUCTION MASTER
CHICAGO, IL—Patients whose non-small cell lung cancers (NSCLC) expressed more than one per cent of the programmed death ligand-1 (PD-L1) tumor proportion score (TPS) lived longer when treated with the anti programmed death 1 (PD-1) antibody pembrolizumab than a control …
AJO Gilberto Lopes and John Heymach PRODUCTION MASTER
CHICAGO—Prophylactic contralateral (CLT) breast radiotherapy was associated with significantly fewer and delayed cases of breast cancer in women having standard therapy for their ipsilateral BRCA mutation-associated breast cancers in a study from Israel reported in a poster session at the …
Ella Evron PRODUCTION MASTER for AJO
BARCELONA—Handgrip strength (HGS) was found to be an independent quantitative marker for overall survival among patients with early-stage non-small cell lung cancer (NSCLC) being treated with stereotactic body radiotherapy (SBRT) in a study discussed at the 2018 European Society for …
Stéphanie Peeters AJO Production MASTER
BARCELONA—Accelerated partial breast irradiation (ABPI) brachytherapy completed in a single week gave at least as good efficacy and safety as other radiotherapy protocols after breast-conserving therapy (BCS) for patients with low-risk breast cancer and brought advantages in terms of symptoms …
Rebekka Schäfer AJO INTERVIEW Production MASTER
BARCELONA—Image-guided adaptive brachytherapy (IGABT) for patients with cervical cancer did not increase risk for ureteral stricture (a rare but feared complication of pelvic radiotherapy) in European research reported at the European Society for Radiotherapy & Oncology (ESTRO 37) 2018 conference.…
Lars Fokdal AJO INTERVIEW Production Master
BARCELONA—It is essential to conduct a comprehensive geriatric assessment of patients over 74 with lung cancer before deciding to escalate treatment dose by switching to concurrent chemo-radiotherapy in an attempt to improve outcomes. This was the conclusion of a phase …
180519 van Loon AJO INTERVIEW Production MASTER
BARCELONA—The accuracy of radiation targeting using image-guided radiotherapy (IGRT) was significantly associated with overall survival in a study of a large cohort of patients treated with IGRT for their lung and esophageal cancers. reported at the 2018 European Society For …
Corinne Johnson AJO Production MASTER
BARCELONA—Women who develop breast symptoms—especially lumps—between regular mammography screening examinations are up to four times more likely to have a diagnosis of breast cancer soon after than women who do not have symptoms according to findings of a massive study …
Deependra Singh AUDIO JOURNAL OF ONCOLOGY
BARCELONA—More pre-menopausal women who have estrogen receptor (ER) positive advanced breast cancer could be spared chemotherapy—according to latest findings from the MONALEESA-7 double-blind randomized phase 3 trial in which either placebo (PBO) or the cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib …
Nadia Harbeck with Emiel Rutgers AJO PRODUCTION MASTER
BARCELONA—A multicenter nationwide Italian study of patients with ductal carcinoma in situ (DCIS) treated with breast conservative surgery (BCS) and whole breast radiotherapy (RT) has updated risk criteria to help women opt for gentler treatments and avoid toxicities from overtreatment.…
Icro Meattini AJO PRODUCTION MASTER
BARCELONA—Not only was breast conserving therapy safer than mastectomy for most low-risk patients in the large randomized EORTC 10041/BIG 03-04 MINDACT trial reported at the 2018 European Breast Cancer Conference but also many patients could be advised to avoid chemotherapy …
Emiel Rutgers AJO PRODUCTION MASTER
BARCELONA—Healthy women with BRCA1 mutations who opted for bilateral prophylactic mastectomy had their lives prolonged in comparison with similar women who did not. But in healthy women with the BRCA2 mutation the procedure did not improve overall survival even though …
BARCELONA—Patients treated for BRCA-associated breast cancers could be given more accurate estimates of the risk for developing second primaries of the contralateral breast by combining polygenic risk scores (PRS) with standard risk factors if study findings reported at the 2018 …
Alexandra van den Broek INTERVIEW
ATLANTA—Six months follow up of the Select-D randomized open label multicenter pilot study with 406 patients has confirmed that therapy with the direct oral anticoagulant (DOAC) rivaroxaban was a safe and effective alternative strategy to standard treatment with the low …
ATLANTA—Six months follow up of the Select-D randomized open label multicenter pilot study with 406 patients has confirmed that therapy with the direct oral anticoagulant (DOAC) rivaroxaban was a safe and effective alternative strategy to standard treatment with the low …
180131 Annie Young INTERVIEW PRODUCTION MASTER
ATLANTA— In patients with a variety of cancers oral therapy with edoxaban—a direct oral anticoagulant (DOAC)—was just as effective and safe in terms of the risks of recurrent venous thromboembolism (VTE) and bleeding as injections with the low molecular weight …
GARY RASKOB Mono INTERVIEW Productdion MASTER
ATLANTA—Adding anti-BCL-2 therapy with the small-molecule drug venetoclax (VEN) to standard low-dose cytarabine (LDAC) chemotherapy tripled response rates over historical comparators and extended survival in older patients with acute myeloid leukemia (AML) who were ineligible for intensification of their chemotherapy …
Andrew Wei INTEVIEW PRODUCTION MASTER
ATLANTA—Subcutaneous administration of the anti-CD 38 monoclonal antibody daratumumab could help more patients get this emerging therapy more easily for their advanced or recently-diagnosed multiple myeloma according to research reported from the Pavo study at the 2017 American Society of …
Ajai Chari MONO INTERVIEW for AJO Production MASTER
MILAN, Italy—Genomic profiling could help reduce the risk of over-treatment in primary prostate cancer (PC) by identifying patients and healthy individuals whose genes put them at greatest risk of developing dangerous disseminated disease said Norman J Maitland PhD, Professor of …
Norman Maitland AJO PRODUCTION Master
MILAN, Italy—The first choice of therapy for patients with metastatic kidney cancer who have failed VEGF therapy has changed according to experts at the 2016 European Multidisciplinary Meeting on Urological Cancers (EMUC) who assessed phase 3 study data on …
Thomas Powles 1 EMUC PRODUCTION Master
MILAN, Italy—Patients with node-positive prostate cancer being treated with prostatectomy could derive benefit from early multimodality therapy combining androgen deprivation therapy (ADT) with radiotherapy (RT)—on top of surgery—if they have pathological features indicating high risk, according to findings reported at …
Karim Touijer EMUC AJO PRODUCTION Master